Eagle Health Investments LP Buys Shares of 369,164 Boston Scientific Corporation $BSX

Eagle Health Investments LP purchased a new position in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, Holdings Channel reports. The institutional investor purchased 369,164 shares of the medical equipment provider’s stock, valued at approximately $15,756,000. Boston Scientific comprises approximately 2.6% of Eagle Health Investments LP’s investment portfolio, making the stock its 16th biggest holding.

Several other institutional investors have also modified their holdings of BSX. Kelleher Financial Advisors bought a new stake in Boston Scientific during the 2nd quarter worth approximately $25,000. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC acquired a new position in Boston Scientific in the 4th quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific in the 1st quarter worth $28,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger acquired 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward J. Ludwig bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 194,522 shares of company stock worth $9,385,210 over the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have issued reports on the company. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Canaccord Genuity Group decreased their price objective on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Truist Financial dropped their target price on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a research note on Thursday, May 28th. Finally, Robert W. Baird set a $56.00 price target on Boston Scientific in a research report on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Trading Up 3.1%

Shares of NYSE:BSX opened at $52.02 on Thursday. The company’s 50-day moving average price is $46.22 and its two-hundred day moving average price is $58.22. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The stock has a market capitalization of $75.39 billion, a PE ratio of 21.06, a price-to-earnings-growth ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.